Pomona, New York — September 30, 2025 — NeuroLight, Inc., a pioneering neurotechnology company developing breakthrough brain state transfer solutions for neurological disorders, today announced the appointment of Frank Nagy, PhD, as Chief Clinical Officer and Director of Business Development. Dr. Nagy brings over a decade of experience in medical affairs leadership and clinical development across neurology, psychiatry, and rare diseases.
In this dual role, Dr. Nagy will oversee NeuroLight’s clinical trial strategy and execution while driving strategic partnerships and business development initiatives. His appointment comes as the company prepares to advance its revolutionary NeuroMask™ device through pivotal clinical trials and FDA regulatory pathways for the treatment of sleep disorders and neurodegenerative diseases.
Dr. Nagy has worked in scientific and healthcare fields for over 20 years in a career that has spanned academic research, digital health, medical technology, biopharma, and healthcare services. Before joining Neurolight, he held executive roles at leading pharmaceutical companies, overseeing clinical and business development. His expertise spans multiple therapeutic areas, with a particular focus on neurology and psychiatry. Frank Nagy is committed to advancing product development and commercialization by delivering differentiated scientific and clinical value. He holds a PhD in Neuroscience and completed a postdoctoral fellowship at Weill Cornell Medical College.
“Dr. Nagy’s unique combination of clinical development expertise and business acumen makes him an ideal addition to our leadership team,” said Alexander Poltorak, Founder and President of NeuroLight. “His proven track record in shepherding innovative therapies through clinical trials and regulatory approval, coupled with his deep understanding of neuroscience, neurology, and neuromodulation, will be instrumental as we advance NeuroMask toward commercialization.”
Dr. Nagy earned his PhD in Neuroscience from Rutgers University and completed his postdoctoral fellowship in Genetics and Neurology at Weill Cornell Medical College. He also holds a BA in Economics with a minor in Physics from Drew University. Throughout his career, he has demonstrated exceptional capabilities in medical affairs strategy, scientific communications, KOL engagement, and cross-functional team leadership.
“I am thrilled to join NeuroLight at this pivotal stage in the company’s development,” said Dr. Nagy. “The potential of brain state transfer technology to transform the treatment landscape for sleep disorders and neurodegenerative diseases is remarkable. I look forward to leveraging my experience in clinical development and strategic partnerships to help bring this groundbreaking technology to patients who desperately need new therapeutic options.” NeuroLight’s proprietary technology, protected by thirteen U.S. patents, European patent, and several pending patent applications, uses non-invasive sensory stimulation to restore healthy sleep patterns and improve cognitive function. The company has completed two pilot studies and developed an alpha prototype with support from NSF/SBIR funding.